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Abstract: We have posited that Odontogenic Ameloblast Associated Protein (ODAM) serves as a novel prognostic biomarker in breast 
cancer and now have investigated its potential role in regulating tumor growth and metastasis. Human breast cancer MDA-MB-231 cells 
were transfected with a recombinant ODAM plasmid construct (or, as a control, the plasmid vector alone). ODAM expression increased 
adhesion and apoptosis of the transfected MDA-MB-231 cells and suppressed their growth rate, migratory activity, and capability to 
invade extracellular matrix-coated membranes. Implantation of such cells into mouse mammary fat pads resulted in significantly smaller 
tumors than occurred in animals that received control cells; furthermore, ODAM-expressing cells, when injected intravenously into 
mice, failed to metastasize, whereas the control-transfected counterparts produced extensive lung lesions. Our finding that induction 
of ODAM expression in human breast cancer cells markedly inhibited their neoplastic properties provides further evidence for the 
  regulatory role of this molecule in tumorigenesis and, consequently, is of potential clinical import.
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Introduction
Breast malignancies are a leading cause of female 
cancer-related deaths in the United States, with an 
estimated world-wide mortality of over 40,000 indi-
viduals in 2010.1 Progress in reducing the societal 
impact  of  this  disease  has  been  limited  due  to  its 
biological and pathological diversity, as manifested 
by distinct phenotypes, differences in prognosis, and 
response  to  therapy.2  The  heterogeneous  nature  of 
breast cancer has been attributed to the variability 
in expression of genes that control cell growth and 
malignant  potential3,4  and,  in  this  regard,  we  have 
reported5 that the protein product of a gene involved 
in  dental  development6,7—Odontogenic Ameloblast 
Associated Protein (ODAM)—is expressed in certain 
human epithelial neoplasms, including breast cancer. 
Notably, this molecule appears to serve as a novel, 
favorable prognostic biomarker of this malignancy, 
as demonstrated by the finding of a statistically sig-
nificant correlation between the nuclear presence of 
ODAM and an improved 5-year survival of patients, 
irrespective of disease stage.8
To gain further insight into the function of ODAM 
and to determine if its upregulation has a protective 
role in carcinogenesis, we transfected highly invasive 
ODAM-negative human breast cancer cells, MDA-
MB-231,9  with  a  cytomegalovirus  promoter-based 
plasmid  construct  encoding  for  ODAM.  We  now 
report the results of our in vitro and in vivo studies 
which have shown that increased ODAM expression 
profoundly  suppressed  the  neoplastic  properties  of 
these cells and, as such, may represent a novel and tar-
geted form of therapy in patients with breast cancer.
Methods
Cell lines and tissue culture
The  human  breast  cancer  cell  lines  MDA-MB-231, 
T-47D, and MCF-7 were obtained from the American 
Type Culture Collection and maintained in a humidi-
fied chamber at 37 °C under 5% CO2 with DMEM/F12 
Hepes medium (Lonza) containing 5% fetal bovine 
serum (FBS, Invitrogen), penicillin (100 units/mL), and 
streptomycin (100 µg/mL). Hela and A549 cells were 
also obtained from ATCC and   maintained similarly.
Recombinant human ODAM
A  full-length  recombinant  (r)  human  ODAM-
pcDNA5T/O (Invitrogen) plasmid construct, which 
included the leader coding sequence, was generated 
using  Phusion  thermal  polymerase  (New  England 
Biolabs)  by  PCR  extension  of  a  pSmart  r-human 
ODAM  cloned  insert  encoding  the  279-residue 
mature  protein,  plus  c-terminal  FLAG  and  8XHis 
epitopes.5 The product was gel purified, inserted into 
the EcoRV position of the pcDNA5T/O multiple clon-
ing site, and the nucleotide sequence of the resultant 
product determined at the University of Tennessee’s 
  Molecular Biology Core facility.
Transfection of breast cancer cells with 
rODAM
MDA-MB-231 cells were transfected with either a 
human ODAM-pcDNA5T/O construct or, as a con-
trol,  the  vector  alone,  using  Lipofectamine  LTX 
reagent (Invitrogen) according to the   manufacturer’s 
protocol.  Growth  selection  was  performed  with 
  hygromycin (400 µg/mL) in 100-mm culture dishes 
and  visible  colonies  were  transferred  into  24-well 
plates. After 7 to 10 days, the media were tested for 
ODAM  production  by  capture  ELISA  (see  below) 
and ODAM-positive and control cell clones (desig-
nated 231-ODAM or 231-CON, respectively) were 
expanded.
Capture eLiSA screening for ODAM 
protein
For  ODAM  detection,  96-well  polystyrene  micro-
titer  plates  (Corning)  were  coated  with  the  anti-
ODAM monoclonal antibody (mAb) 5A1,5 blocked 
with bovine serum albumin (BSA, Sigma-Aldrich), 
and  filled  with  200  µL  of  cell  culture  supernatant 
from    putative  ODAM-expressing  clones.  After  a 
1-h  incubation  at  37  °C,  wells  were  washed  with 
PBS/0.1%  Tween  20  (Sigma-Aldrich),  incubated 
with  biotinylated  anti-ODAM  mAb  8B4  and,  fol-
lowing  further  washes,  exposed  to  peroxidase-
  conjugated    streptavidin.5  Finally,  after  addition  of 
the ABTS peroxidase substrate, bound biotinylated 
anti-ODAM mAb was measured at 405 nm using a 
BioTek   Synergy HT plate reader.
Detection of rODAM
Transfected cells were plated onto 22-mm glass cover-
slips (Fisher) in 6-well BD Falcon tissue culture plates 
(BD Biosciences) and, 72 h later, washed with PBS, 
fixed with 4% paraformaldehyde,   permeabilized with Breast cancer cells inhibited by ODAM expression
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0.25% Triton X-100/PBS, and blocked with 3% BSA 
in PBS. To detect intracellular ODAM, the cells were 
exposed, first to mAb 8B4, and then to   AlexaFluor488 
goat anti-mouse IgG (Invitrogen); the cell nuclei were 
counterstained  with  Hoescht  33342    (Invitrogen). 
  Cellular F-actin was visualized in fixed/  permeabilized 
cells stained with AlexaFluor488-  conjugated Phalloi-
din (Invitrogen) and Hoescht 33342.
Western blotting
For Western blots, supernatants from 72-h   231-CON 
and 231-ODAM cultures were centrifuged at 2000 × g 
to  remove  cellular  debris  and  the  rODAM  bound 
via the HIS-tag to Co++-iminodiacetic acid agarose 
resin was released with 50 mM EDTA. An aliquot 
was removed, electrophoresed on a 10% bis-Tris gel 
(Invitrogen), and ODAM detected using a combina-
tion of anti-ODAM mAbs 8B4 and 5 A1, as described 
previously.5,10  For  determination  of  Triton-soluble 
and total vimentin levels, cultured cells were washed 
in PBS and lysed either in a Triton buffer (20 mM 
Tris,  pH  7.5,  150  mM  NaCl,  0.5%  Triton  X-100, 
0.5 mM PMSF) or in the same buffer supplemented 
with 0.5% deoxycholic acid and 0.1% sodium dode-
cyl  sulfate  (RIPA  buffer),  followed  by  centrifuga-
tion at 15,000 × g for 20 min at 4 °C.11 Supernatants 
were electrophoresed and blotted using a mouse anti-
  vimentin mAb (sc-32322, Santa Cruz Biotech). As a 
control for detergent extraction of vimentin, the blot 
was stripped in glycine/SDS (pH, 2.5) and re-probed 
with an anti-b actin antibody (clone AC-74, Sigma).
Cell growth and aggregation assays
231-ODAM  and  231-CON  cells  were  trypsinized, 
counted, and plated in quadruplicate in 24-well tissue 
culture plates at a concentration of 1 × 104 cells/well. 
One, 4, 7, and 10 days later, cells were fixed by addi-
tion of 4% glutaraldehyde, washed with water, dried, 
and then stained with 0.1% crystal violet. After another 
wash  and  solubilization  with  10%  acetic  acid,  the 
cell content was measured by absorbance at 562 nm. 
Growth rates were determined by linear regression 
analysis  using  GraphPad  Prism  4.0  software.  For 
cell aggregation assays, subconfluent 231-CON and 
231-ODAM cultures were treated with trypsin-EDTA 
(Lonza) for 15 min, washed twice in PBS, suspended 
in Hank’s Balanced Salt Solution lacking Ca++ and 
Mg++ (Lonza), and plated at 1 × 105 cells/mL in 1% 
agar-coated 6-well tissue culture plates. After incuba-
tion for 3 h at 37 °C on a rotating shaker set at 80 rpm, 
the extent of aggregation was visualized microscopi-
cally and multiple representative fields were photo-
graphed for comparative purposes.
BrdU labeling
231-ODAM and 231-CON cells were trypsinized and 
plated at 2 × 105 cells/well on 22-mm glass coverslips 
(Fisher) in 6-well tissue culture plates (BD Falcon). 
After 3 days, the cultures were pulsed for 3 h with 
50 µM BrdU (Sigma-Aldrich), fixed with cold 70% 
ethanol, and blocked by addition of 3% BSA. Cellular 
DNA was denatured with 2 N HCl/0.5% Triton X-100, 
followed by 3 PBS washes. Intracellular incorpora-
tion of BrdU was detected using an AlexaFluor488-
conjugated anti-BrdU antibody (Invitrogen); nuclei 
were  counterstained  with  Hoescht  33342.  Six  rep-
resentative 200× fields containing .1000 cells from 
each group were photographed and the labeled versus 
unlabeled nuclei counted.
Apoptosis assays
231-ODAM  and  231-CON  cells  were  plated  at  a 
range of cell densities to yield (at 72 h) high density 
(1.2 × 105 cells/cm2) and low density (3 × 104 cells/cm2) 
cultures. The extent of apoptosis was determined by 
measurement of soluble chromatin, using a Cell Death 
Detection ELISA (Roche Diagnostics) as described by 
the manufacturer. After staining with Annexin V-FITC/
propidium iodide (BD Biosciences), the percentage 
of apoptotic cells present in the high density cultures 
was  quantitated  by  flow  cytometry  using  a  Becton 
Dickinson  FACScan  flow  cytometer;  data  from  a 
minimum of 5000 events were collected in 2 separate 
experiments. For determination of caspase-3 activa-
tion, 231-ODAM and 231-CON cells from the high-
density cultures were lysed in 10 mM Tris-PBS, pH 
7.6 containing 1% Triton X-100 and 10 mM sodium 
pyrophosphate. Five µL of the lysate were added to 
100 µL of the assay buffer (10 mM Hepes, pH 7.5/10% 
glycerol/2 mM dithiothreitol) containing 20 µM of the 
fluorogenic caspase-3 substrate Ac-DEVD-AMC (BD 
Biosciences), as per manufacturer’s instructions. After 
1-h incubation at 37 °C, the fluorescent product was 
measured in a BioTek Synergy HT plate reader (exci-
tation and emission wavelengths, 360 and 440 nm, 
respectively).Kestler et al
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Cell-substrate adhesion assays
Polystyrene 96-well tissue culture plates were coated 
overnight at 4 °C with 50 µL/well of either Matri-
gel (Becton Dickinson), Type IV collagen (Sigma-
  Aldrich), or BSA, each at a concentration of 50 µg/mL. 
After washing with PBS, the wells were filled with 
50 µL of suspended, trypsinized 231-ODAM or con-
trol cells (5 × 105 cells/mL) and the plates incubated 
at 37 °C for 40 min.12 After washing with PBS, the 
cells were fixed for 30 min with 4% glutaraldehyde 
and washed with water. The number of bound cells 
was determined after staining with 0.1% crystal vio-
let and solubilization with 10% acetic acid by mea-
surement of the amount of dye released (absorbance, 
562 nm).13 To correct for non-specific binding, the 
average absorbance values in BSA-coated wells were 
subtracted from those derived experimentally.
Cell migration and invasion assays
Trypsinized  231-ODAM  and  231-CON  cells  were 
washed and suspended (1 × 106 cells/mL) in serum-
free DMEM/F12 medium and a 100 µL aliquot was 
placed in the upper chamber of a Costar Transwell per-
meable support (8-µm pore size); the lower chamber 
was filled with 0.7 mL of DMEM/F12 medium with 
10% FBS serving as a chemoattractant. After incuba-
tion at 37 °C for 18 h, the membrane was fixed in etha-
nol and stained with HEMA3 Wright-Giemsa (Fisher 
Scientific). Non-migrating cells were swabbed from 
the upper surface and those that passed through to the 
lower surface were photographed and   counted.11 For 
barrier invasion assays, membranes were pre-coated 
with 40 µL of Matrigel (0.25 mg/mL) and assayed as 
above for cell migration.
in vivo studies
All animal experiments were conducted in accordance 
with United States Public Health Service guidelines 
and  under  the  auspices  of  protocols  approved  by 
the University of Tennessee’s Animal Care and Use 
Committee.
Xenografts  of  trypsinized,  washed  231-ODAM 
and 231-CON cells suspended in PBS (3 × 107 cells/
mL)  containing  50%  Matrigel  were  established 
in  groups  of  5  severe  combined  immunodeficient 
(SCID)-beige 9-wk old female mice (Charles River) 
or Rag-1 immunodeficient mice (from the University 
of   Tennessee Graduate School of Medicine mouse 
colony)  by  100-µL  subcutaneous  injections  into 
the right inguinal mammary fat pads. Six wks later, 
the  animals  were  euthanized  and  the  tumors  were 
removed, weighed, fixed in formalin, and embedded 
in paraffin blocks. To determine the metastatic poten-
tial of the cells, similar groups of mice were given, 
via tail vein, injections of 8 × 105 cells. Thirty-one 
days later, the animals were imaged by PET/CT (see 
below) and lung tissue harvested for microscopic and 
immunohistochemical examination.
Tumor imaging
3’deoxy-3’[18F-fluoro-thymidine]  (18FLT)  was  syn-
thesized using the Advion NanoTek LF flow-based 
microfluidic chemistry system.14 Mice were injected 
in the lateral tail vein with ∼200 µCi of radiotracer 
in 200 µL PBS containing ,10% ethanol, and 1-h 
later, after sacrifice by isoflurane inhalation overdose, 
PET and CT images were generated using an Inveon 
Trimodality SPECT/PET/CT scanner. PET data were 
acquired over 15 min and reconstructed by means of 
the iterative maximum a posteriori (MAP) algorithm 
with a zoom and b-factor of 2 and 0.001, respectively. 
CT data were collected using 360 azimuths over 360° 
of rotation with an exposure time of 240 msec. The 
X-ray voltage and current were 80 kVp and 500 µA, 
respectively. Images were reconstructed with a filtered 
backprojection algorithm on a 2048 × 3072 matrix 
with an effective voxel size of 55 µm. PET and CT 
images  were  co-registered  automatically  and  ana-
lyzed using the Inveon Research Workplace software 
(Siemens Preclinical Solutions).
immunohistochemistry
Four µm-thick formalin-fixed, paraffin embedded tis-
sue sections were mounted on poly-L-lysine-coated 
slides,  dried  overnight  at  room  temperature,  and 
deparaffinized. Slides were immersed in Glyca pH 
4.0  antigen–retrieval  solution  (BioGenex),  heated 
in a microwave oven, and immunostained with the 
anti-ODAM mAb 8B4, using the ImmPRESS polym-
erized reporter enzyme-linked system (Vector Labo-
ratories), as previously described.15 Ki-67 expression 
was determined utilizing the MIB-1 anti-Ki-67 anti-
body (Dako) and the number of positive nuclei in the 
most active growth regions of the tumors enumerated 
in 4 representative 200× fields from each of 5 mice.16 
Active  caspase-3  expression  was  visualized  with Breast cancer cells inhibited by ODAM expression
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a rabbit anti-cleaved caspase-3 (Asp175) polyclonal 
antibody (Cell Signaling Technology).
Transient transfection assays of cell 
proliferation and apoptosis
MDA-MB-231  and  MCF-7  cells  were  cultured 
in 24-well plates or on 15-mm coverslips at ∼30% 
confluency  and  transfected  with  1  µg/well  of  the 
ODAM-pcDNA5T/O or control vector, each in com-
bination with 0.15 µg of pEGFPN1 vector (Clontech) 
as a marker of cell transfection. After 72 h incuba-
tion, 24 well cultures were assayed for apoptosis by 
ELISA as above. Cells on cover slips were labeled 
for 2 h with BrdU and its incorporation in transfected 
cells analyzed by co-staining GFP and BrdU using 
rabbit anti-GFP and AlexaFluor594-conjugated anti-
rabbit  antibodies  (Invitrogen)  and  AlexaFluor488-
  conjugated  anti-BrdU.  BrdU-positive  nuclei  were 
counted as a fraction of GFP-positive cells in 9 fields 
for each transfected culture.
Results
induction of ODAM expression  
in human breast cancer cells
Human r-ODAM (containing the full coding sequ-
ences including the secretory leader plus 3’-FLAG 
and -8XHis epitopes) was transiently expressed as 
a pcDNA5/TO construct in MDA-MB-231, MCF-7, 
and Hela cells, as evidenced immunocytologically and 
by an ELISA of culture fluid supernatants. This pro-
tein was not detected in control vector-transfected or 
untreated cells. As seen in Table S1 (see supplemental 
data), only one cell line, MDA-MB-231, was capa-
ble of sustained ODAM expression after antibiotic 
  selection. In contrast, 4 different human neoplastic 
cell lines (including 2 others of breast origin) showed 
no evidence of continued rODAM expression.
As illustrated in Figure 1A, cells from the most 
prolific MDA-MB-231 clone (#32), designated 231-
ODAM, were immunostained by the anti-ODAM spe-
cific mAb 8B4 at the cell matrix/border, as well as the 
nuclear/paranuclear regions, presumably in the Golgi 
apparatus. Additionally, 5 to 10 ng/mL of ODAM was 
detected by capture ELISA in culture fluid superna-
tants from cells grown to confluency. Its presence also 
was revealed by Western blot analysis of the media, 
albeit  at  a  higher  than  predicted    molecular  mass 
(49 versus 29 kDa) due to   glycosylation (Fig. 1B).6 
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Figure 1. Recombinant ODAM expression in MDA-MB-231 breast   cancer 
cells.  A)  Reactivity  (green  immunofluorescence)  of  anti-ODAM  mAb 
8B4 with hoechst 33342-stained control vector (231-COn) and ODAM-
  transfected (231-ODAM) cells (original magnification, ×400). B) Western 
blot analysis of 231-ODAM clone #32 culture fluid supernatant (the Mr 
markers are as indicated).
Notably, there was no evidence in the immunoassays 
of ODAM expression by vector-only transfected cells 
(designated 231-CON).
effect of ODAM expression on properties 
of human breast cancer cells
In a series of in vitro experiments, we compared the 
properties  of  cells  obtained  from  the  stably  trans-
fected  231-ODAM  clone  #32  with  those  of  plas-
mid  vector-transfected  controls.  The  number  of 
  ODAM-expressing  cells  was  4-fold  less  than  that 
of the controls after 10 days in culture (Fig. 2A), as 
also shown with a second 231-ODAM clone (sup-
plemental Fig. S1A). Further, their low growth rate 
was  evidenced  by  limited  incorporation  of  BrdU 
(Fig.  2B).  ODAM-expressing  MDA-MB-231  cells 
had an increased rate of apoptosis relative to control 
cultures, especially at higher cell densities where the 
apoptotic fraction in 231-ODAM cultures was found 
to be ∼2.5 times that of the controls (Fig. 2C, D). This 
effect was associated with a demonstrable increase 
in caspase-3 activation (Fig. 2E). Transient transfec-
tion assays indicated that ODAM expression inhib-
ited MCF-7 cell proliferation by 48%, as measured by 
BrdU incorporation after 72 h, and to a lesser degree, 
that of MDA-MB-231 cells (31%) (Supplemental Fig. 
S2A).  Transient  ODAM  expression  also  increased 
by four-fold the extent of apoptosis in MCF-7 cells 
(Supplemental Fig. S2B), whereas this effect did not 
occur with MDA-MB-231 cells.
The  results  of  studies  (Fig.  3A)  measuring  the 
binding of 231-ODAM cells to Matrigel- or type IV 
collagen-coated plates revealed significantly greater 
attachment (P , 0.01) than did the 231-CON cells. Kestler et al
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ODAM expression in MDA-MB-231 cells also elic-
ited  a  significant  increase  in  their  ability  to  form 
cell aggregates (Fig. 3B and Fig. S1B). Analysis of 
F-actin organization by phalloidin staining (Fig. 4A) 
revealed  rearrangement  of  the  visible  stress  fibers 
to  circumferential  cables.17–19 Additionally,  ODAM 
expression resulted, not only in a striking increase 
in soluble vimentin (whereas overall vimentin lev-
els  were  unchanged,  Fig.  4B),  but  also  decreased, 
by ∼50% (P , 0.01), the capability of these cells to 
migrate towards a chemoattractant, (Fig. 5A), as well 
as penetrate and invade a Matrigel barrier (Fig. 5B).
effect of ODAM expression  
on the neoplastic potential  
of human breast cancer cells
To determine if ODAM expression would affect the 
aggressive tumor-forming and metastatic properties of 
MDA-MB-231 cells in vivo,9 231-ODAM and con-
trol cells (3 × 106) were suspended in 50%   Matrigel 
and injected into the inguinal mammary fat pads of 
SCID-beige mice (5 per group). Within 6 wks, the 
tumors  in  those  animals  that  received  the  control 
cells had grown to ∼1 cm, whereas those formed by 
the    ODAM-transfected  counterparts  were  ∼16-fold 
smaller in size and, in some cases, barely detectable 
(Fig. 6A). Additionally, they had considerably reduced 
Ki-67 expression (31% versus 83%; P , 0.01; Fig. 6B) 
and caspase-3 was readily detected in localized areas 
of the 231-ODAM xenografts while, in the 231-CON 
tumors, only rare, single cells contained the activated 
enzyme (Fig. 6C). Similarly, the growth of tumors 
generated from injection of MDA-MB-231 ODAM-
transfected  cells  (clones  32  and  20)  into  a  second 
immunocompromised  animal,  ie,  Rag-1  mice,  was 
comparably inhibited, as shown in Figure S1C.
In other experiments, groups of SCID mice were 
given  intravenous  injections  of  8  ×  105  ODAM-
  transfected  or  control  MDA-MB-231  cells.  By 
31 days, the latter animals were in obvious distress 
C B
**
0
25
50
231-
CON
231-
ODAM
231-
CON
231-
ODAM
231-
CON
231-
ODAM
231-
CON
231-
ODAM
231-
CON
231-
ODAM
A
0.0
0
1
2 **
**
0
1
2
3
4
Low density
**
0
10
20
30
40
D
**
0
10
20
30
E
Days in culture
C
e
l
l
 
m
a
s
s
 
(
a
b
s
o
r
b
a
n
c
e
)
B
r
d
U
-
l
a
b
e
l
e
d
 
n
u
c
l
e
i
 
(
%
)
D
N
A
 
f
r
a
g
m
e
n
t
a
t
i
o
n
A
p
o
p
t
o
t
i
c
 
c
e
l
l
s
 
(
%
)
C
a
s
p
a
s
e
 
3
 
a
c
t
i
v
i
t
y
10.0 7.5 5.0 2.5
High density
Figure 2. ODAM expression inhibits growth and elicits apoptosis of MDA-MB-231 cells. A) growth rates of 231-COn () and 231-ODAM (∆) cells. Plotted 
values represent absorbance and are given as mean ± 1 standard deviation for 4 replicates. B) DnA replication in 231-COn and 231-ODAM cultures, as 
depicted as percent of BrdU-labeled nuclei. Data are given as the mean ± 1 standard deviation (**P , 0.01) as measured in 6 fields from 2 independent 
cultures (.1000 cells). c) Relative apoptosis in low- and high-density cultures of 231-COn and 231-ODAM cells. Determinations were based on a soluble 
chromatin eLiSA where the values are given as the mean ± 1 standard deviation (**P , 0.01) from triplicate cultures. D) Apoptotic fractions in high density 
cultures of 231-COn and 231-ODAM cells based on Annexin V staining. Values are given as the mean ± 1 standard deviation (**P , 0.05) from 2 inde-
pendent experiments. e) Caspase-3 activation in 231-CON and 231-ODAM cells. Values for the extent of fluorogenic caspase-3 substrate cleavage are 
given as the mean ± 1 standard deviation (**P , 0.01) from triplicate cultures.Breast cancer cells inhibited by ODAM expression
Breast Cancer: Basic and Clinical Research 2011:5  79
due  to  extensive  multinodular  pulmonary  metasta-
ses that were metabolically active, as evidenced by 
18FLT  micro-PET/CT  scans  (Fig.  7A).  In  contrast, 
those that received the 231-ODAM cells essentially 
had no lung lesions by imaging. The mean activi-
ties  measured  in  0.4  mm3  areas  of  interest  in  the 
lungs  were  0.643  MBq/cm3  for  231-CON  [n  =  1] 
and 0.083 ± 0.062 MBq/cm3 [n = 3] for 231-ODAM 
recipients.  In  necropsy  sections  of  mice  receiving 
231-ODAM  cells  only  rare  tumor  deposits  were 
found lodged in alveolar septal capillaries, with no 
evidence of invasion, and a complete lack of fibrosis, 
desmoplasia, or other host response (Fig. 7B).
Discussion
Historically, a portion of the gene encoding ODAM 
was recognized initially through the Japanese NEDO 
human cDNA-sequencing project where messenger 
RNA specifying the C-terminal 153 amino acids was 
cloned from the KATO III signet-ring gastric carci-
noma cell line.20 Subsequently, the coding sequence 
representing the entire 279-residue protein was iden-
tified  and  homologous  nucleotide  sequences  were 
detected in certain fetal and adult tissues.21 The first 
evidence of the expressed protein resulted from our 
analyses of amyloid associated with calcifying epithe-
lial odontogenic (Pindborg) tumors, where the fibrils 
were found to consist of ODAM-related peptides.22,23 
Although the biological function of ODAM has not 
been established, it undoubtedly has a fundamental 
role in odontogenesis6,7 and is upregulated in human 
gastric cancers.5,24
To gain further insight into the potential role of 
ODAM  expression  in  tissue  development  and  car-
cinogenesis, we generated mAbs specific for this pro-
tein and demonstrated that these reagents recognized 
ODAM molecules, not only in ameloblasts, but also 
in  certain  normal  epithelial  and  malignant  tissues, 
especially those of breast origin where its presence 
was detected at the molecular level through RNA and 
in situ hybridization analyses.5 Further, we found in 
a retrospective study of archival breast cancer speci-
mens that patients whose tumor cells expressed nuclear 
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tion for 10 replicates (**P , 0.01). B) Cell-cell aggregation of trypsinized 
231-COn and 231-ODAM cells after 3 h in suspension culture (original 
magnification, ×40).
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Figure 4. ODAM expression elicits cytoskeletal rearrangement in MDA-
MB-231 cells. A) F-actin arrangement in 231-COn and 231-ODAM cells 
was visualized by Phalloidin staining (green) with nuclei counterstained 
(blue); original magnifications, ×400). B) Western blot detection of Triton 
X-soluble vimentin (top panel), soluble b-actin (middle panel), and total 
vimentin (bottom panel) in 231-COn and 231-ODAM cultures.Kestler et al
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ODAM had an improved survival rate,   irrespective of 
disease stage.8
Based on our results, we posit that ODAM expres-
sion may have a mitigating effect in breast   neoplasia. 
When  the  highly  aggressive  human  breast  cancer 
cells MDA-MB-2319 were transfected with a gene 
construct encoding this molecule, their tumorigenic 
properties  were  significantly  lessened,  ie,  growth 
rate, migration, and invasiveness were reduced, while 
adhesion to extracellular matrices, cell-cell associa-
tion, and rate of apoptosis were increased.   Notably, 
these effects on cell proliferation and apoptosis also 
occurred  upon  transient  expression  of  ODAM  in 
MCF-7 human breast cancer cells indicating that these 
consequences of ODAM expression are not limited to 
MDA-MB-231 cells.
Strikingly,  and  in  contrast  to  vector-only  trans-
fected controls, ODAM-positive MDA-MB-231 cells 
implanted into the mammary fat pads of SCID-beige 
mice grew at a significantly lower rate, resulting in 
harvested tumors of 16-fold lower mass.   Furthermore, 
ODAM-transfected cells injected intravenously into 
the  tail  veins  of  SCID  mice  failed  to  form  inva-
sive  lung  metastases,  as  opposed  to  the  extensive 
  pulmonary lesions seen in recipients of the MDA-
MB-231 vector-only control cells.
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Figure  5.  ODAM  expression  inhibits  migration  and  Matrigel-barrier 
  invasion  of  MDA-MB-231  cells.  A)  Transwell  migration  of  231-COn 
and  231-ODAM  cells  (Wright-Giemsa,  original  magnifications,  ×200). 
B)   Matrigel-barrier invasion of 231-COn and 231-ODAM cells.   Undersides 
of Matrigel-coated, Wright-giemsa-stained Transwell membranes (cell 
counts from 8 representative fields are given as the mean ± 1   standard 
deviation [**P , 0.001]).
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Figure 6. ODAM expression suppresses the development in mice of 
MDA-MB-231 solid tumor xenografts. A) Tumors harvested from the right 
mammary fat pads of SCiD beige mice 6 wks after implantation of 3 × 106 
231-COn or 231-ODAM cells in 50% Matrigel. graphic representation of 
average tumor masses from 5 mice in each group ± 1 standard deviation 
(**P , 0.001). B) Ki-67 expression in 231-COn and 231-ODAM tumors 
(original magnifications, × 200). graphic representation of the percentage 
of Ki-67-positive nuclei in the 2 types of xenografts, as determined from 
5 representative fields (**P , 0.01). c) Activated caspase-3 in   231-COn 
and 231-ODAM tumors (original magnifications, ×200).Breast cancer cells inhibited by ODAM expression
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and, like ODAM, reside in the cytoplasm, nuclear/
paranuclear regions, and at the cell surface.32 Further, 
ODAM contains 6 PDZ-binding motifs that are found 
in several tight junction proteins, including VMP-1, 
JAM-A, claudin-4, and ZO, all of which have been 
implicated in malignant transformation, cell signal-
ing, and specifically, breast tumor cell invasion.28,30–37
Ectopic expression of other genes, eg, ER (p29),38 
KRT-18,39  NET-6,40  or  sFRP1,41  has  been  shown  to 
reduce  proliferative  potential  and  tumorigenicity  in 
MDA-MB-231  human  breast  cancer  cells  through, 
for example, interference with the epithelial to mes-
enchymal transition of the tumor cells, upregulation of 
pro-apoptotic proteins, or attenuation of Wnt-  pathway 
signaling by blockade of ligand binding.5–7,8,31,42 ODAM 
shares a number of properties of the proteins encoded 
by these genes in that it is present in cell junctions and 
inhibits tumor cell growth, while enhancing apopto-
sis and promoting actin cable formation reflective of 
a  more  differentiated  state.18,19    However,  ODAM  is 
unique since it seemingly is limited to particular epi-
thelial tissues and its secreted product is localized both 
to  cell  membrane/tissue  interfaces  and  the  nucleus, 
suggesting that this molecule has multiple regulatory 
functions.5–8,31,42 Most notably, ODAM expression rep-
resents a favorable prognostic biomarker, as evidenced 
by our finding of lengthened survival in patients with 
breast cancer, regardless of tumor stage.8
The presence of ODAM in the nucleus has been 
reported to upregulate expression of matrix metallo-
proteinase MMP-20 by binding to its promoter region 
in cultured ameloblasts, while ODAM expression in 
these cells is, in turn, upregulated through interaction 
of the Runx2 transcription factor with the ODAM 
genomic promoter region.43 Runx2 is expressed dur-
ing  normal  mammary  gland  development,  as  well 
as in breast cancer where it is associated with bone 
metastases.44–47 In addition, Runx2 activates the Indian 
Hedgehog pathway48 and has been shown to interact 
directly with the Hedgehog-regulated Gli2 transcrip-
tion factor.49 Further, the related molecule, Gli-1, has 
been associated with adverse breast cancer   prognosis 
and is expressed, along with ODAM, in breast, lung, 
and  gastric  tumors.5,50–53 Additionally,  inhibition  of 
Runx2 expression in MDA-MB-231 cells results in 
loss  of  tumorigenicity.44  The  coactivator  activator 
protein (CoAA) is a negative modulator of Runx2 that 
complexes with its DNA-binding domain and prevents 
A
B
231-CON 231-ODAM
231-CON 231-ODAM
Figure 7. ODAM expression suppresses development in mice of MDA-
MB-231 lung metastases. A) Representative volume-rendered, dorsal 
view images of  18FLT accumulation (false colored green) in the lungs 
of 231-COn and 231-ODAM mice 31 days after intravenous injection of 
8 × 105 cells. B) Representative hematoxylin/eosin-stained lung tissues 
from 231-COn and 231-ODAM injected mice (3 from each group, original 
magnifications, ×200).
We attribute the in vitro and in vivo reduction of 
tumorigenicity induced by ODAM expression, in part, 
to the role of this protein in modulating   cellular junc-
tional interactions and mobility.6,25,26 In this regard, 
a  number  of  other  cell-adhesion  molecules,  eg, 
cadherins,27 ZO-2,28 profilin,29 claudin,30 and AF-6,31 
also have been shown to exhibit anti-tumor properties Kestler et al
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Runx2-mediated  transcriptional  activation  of  other 
genes resulting in effects similar to those exhibited 
by MDA-MB-231 cells after Runx2 inhibition.44,54,55 
Notably,  ODAM  contains  2  of  these  inhibitory 
Runx2-binding motifs that are found in CoAA. Thus, 
interactions of ODAM with Runx2 could contribute 
to suppression of the neoplastic properties of MDA-
MB-231  cells.  However,  suppression  of  Runx2  in 
MDA-MB-231 cells has been shown to be limited to 
an anti-proliferative effect, whereas ODAM effects 
both  proliferation  and  tumorigenicity,  suggesting 
a broader role for ODAM in cellular development, 
renewal, and malignancy.5–8,24,43,56,57
In summary, our studies provide evidence for a func-
tional role of this novel gene product, ODAM, in sup-
pressing the growth rate, invasiveness, and metastatic 
potential of highly invasive human breast   cancer cells. 
Given the favorable clinical prognosis that is associated 
with its expression by tumors, we posit that targeted 
upregulation of the ODAM gene may be of unique ther-
apeutic benefit which could lead to a reduction in the 
morbidity and mortality associated with breast cancer 
and, possibly, other human epithelial malignancies.
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Table s1. hygromycin selection results for recombinant 
ODAM-expressing clones.
cell line Tissue number  
of clones
ODAM-expressing 
clones
A549 Lung 78 0
hela Cervical 71 0
MCF-7 Breast 41 0
T-47D Breast 35 0
MDA-MB-231 Breast 36 17
notes:  human  tumor  cell  lines  were  transfected  with  eukaryotic 
expression  plasmid  PCDnA5T/O  containing  the  full  length  rODAM 
open reading frame under control of the CMV promoter and subjected 
to selection with hygromycin. Resultant clones were tested for ODAM 
expression  by  capture  eLiSA  and  scored  as  negative  or  positive  for 
r-ODAM expression.
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Figure s1. effects of ODAM expression on growth, aggregation, and 
tumorigenicity  of  2  different  stably  transfected  MDA-MB-231-ODAM 
clones. A) growth rates of 231-COn (), 231-ODAM clone #32 (∆), and 
231-ODAM clone #20 (○) cells. Plotted values represent absorbance and 
are given as mean ± 1 standard deviation for 4 replicates. B) Cell aggre-
gation assay for suspension cultures of 231-COn, 231-ODAM clone #32, 
and 231-ODAM clone #20. c) graphic representation of tumor xenograft 
masses  for  231-COn,  231-ODAM  clone  #32,  and  231-ODAM  clone 
#20  cells  6  wks  after  implantation  into  Rag-1  immunodeficient  mice. 
  Values represent the averages of tumor masses from 5 mice in each 
group ± 1 standard deviation (**P , 0.01).
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